Abbott (ABT) Rises As Market Takes a Dip: Key Facts
📈 Abbott (ABT) shares closed up 1.12% at $103.09, outpacing the S&P 500's daily loss.
📉 The stock has fallen 8.36% over the past month, lagging the Medical sector's decline.
💰 Analysts expect Abbott to report EPS of $1.43 and revenue of $12.91 billion in the upcoming quarter.
📊 Consensus estimates project annual earnings of $5.52 per share with 7.18% growth.
🔍 Recent positive analyst estimate revisions signal optimism regarding Abbott's near-term business trends.
💵 Abbott trades at a Forward P/E of 18.46, which is below the industry average of 20.16.
📉 The company holds a Zacks Rank of #3 (Hold) with a PEG ratio of 1.89.
Bullish Signals
- Abbott shares rose 1.12% to close at $103.09, outperforming the S&P 500 during a market dip.
- Analysts anticipate a 10% year-over-year increase in EPS to $1.43 for the upcoming quarter.
- Revenue is forecasted to grow 13.52% sequentially to $12.91 billion, indicating strong top-line momentum.
- Recent positive revisions to analyst estimates suggest growing confidence in Abbott's profitability and business trends.
- The company trades at a Forward P/E of 18.46, offering a valuation discount compared to the industry average of 20.16.
Risk Factors
- The stock has declined 8.36% over the past month, significantly underperforming the Medical sector's loss of 2.01%.
- Abbott currently holds a Zacks Rank of #3 (Hold), indicating neutral analyst sentiment rather than a strong buy rating.
Full Analysis
Abbott Laboratories (ABT) shares closed at $103.09, rising 1.12% to outperform the broader market despite a downturn in major indices like the S&P 500 and Nasdaq. However, the stock has underperformed over the past month, falling 8.36% compared to a smaller decline for the Medical sector and the S&P 500.
Investors are closely watching Abbott's upcoming earnings release, with consensus estimates projecting an EPS of $1.43, representing a 10% year-over-year increase. Revenue is expected to reach $12.91 billion, marking a significant 13.52% growth from the prior quarter.
Analyst sentiment remains cautiously optimistic, reflected in recent positive revisions to earnings estimates which typically correlate with share price momentum. Abbott currently trades at a Forward P/E of 18.46, offering a discount relative to its industry average of 20.16.
